|
SPORE in Lymphoma
|
5P50CA126752-12
|
$2,297,796
|
$620,405
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
City of Hope Lymphoma SPORE
|
2P50CA107399-11A1
|
$2,500,000
|
$900,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
$130,594
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
|
5R01CA047006-31
|
$532,500
|
$266,250
|
ZHAO, BO
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$90,276
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$834,152
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Improving Hospice Use for Patients with Blood Cancers
|
5K08CA218295-02
|
$173,698
|
$43,425
|
ODEJIDE, OREOFE
|
DANA-FARBER CANCER INST
|
|
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
|
5R01CA161026-08
|
$373,399
|
$186,700
|
SHIPP, MARGARET
|
DANA-FARBER CANCER INST
|
|
Demonstrating the feasibility of CCG-257081 as a preventive therapy to inhibit bleomycin-induced lung fibrosis in mice
|
1R43CA235823-01
|
$300,000
|
$300,000
|
VARNUM, MEGAN
|
FIBROSIX, LLC
|
|
Optimal Antiretroviral Therapy During Bone Marrow Transplant in HIV-1 Infection
|
5K23CA177321-05
|
$161,608
|
$64,643
|
DURAND, CHRISTINE
|
JOHNS HOPKINS UNIVERSITY
|
|
TAS::75 0849::TAS ADMINISTRATIVE MODIFICATION
|
261200800001E
|
$313,286,406
|
$666
|
DMITROVSKY, ETHAN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Smartphone for molecular cancer diagnostic in Africa
|
4UH3CA202637-03
|
$973,275
|
$486,638
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$22,000
|
N/A
|
National Institutes of Health
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
$30,758
|
Barr, Frederic
|
CCR (NCI)
|
|
Pooling project of NCI and Cross-Canada studies
|
ZIA CP010119 10649
|
$80,847
|
$16,169
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
Follow-up studies from the NHL/LM GWAS
|
ZIA CP010136 10799
|
$47,640
|
$4,764
|
Berndt, Sonja
|
DCEG (NCI)
|
|
Medical Oncology Fellowship Program
|
ZIE BC 010843
|
$3,561,926
|
$178,096
|
Bilusic, Marijo
|
CCR (NCI)
|
|
SEER, Registries, and Special Projects
|
ZIA CP010131 10560
|
$30,751
|
$3,075
|
Cahoon, Elizabeth
|
DCEG (NCI)
|
|
Radiation Oncology Branch - Radiation Clinic
|
ZID BC 010990
|
$5,352,849
|
$428,228
|
Camphausen, Kevin
|
CCR (NCI)
|
|
CCR Genomics Core
|
ZIC BC 011623
|
$665,279
|
$66,528
|
Conner, Elizabeth
|
CCR (NCI)
|
|
Dermatology Consultation Service
|
ZID BC 011317
|
$9,978
|
$2,993
|
Cowen, Edward
|
CCR (NCI)
|
|
Basic and Preclinical Animal Models in support of Cancer and HIV-AIDS Research
|
ZIG BC 010856
|
$14,857,052
|
$742,855
|
Custer, Mary
|
CCR (NCI)
|
|
HIV and Cancer
|
ZIA CP010150 10071
|
$63,128
|
$9,469
|
Engels, Eric
|
DCEG (NCI)
|
|
Registry linkage projects [including Scandinavia, SEER Medicare, other]
|
ZIA CP010150 10359
|
$120,247
|
$24,049
|
Engels, Eric
|
DCEG (NCI)
|
|
Cancer Risk in Solid Organ Transplant Recipients
|
ZIA CP010150 10362
|
$146,079
|
$7,304
|
Engels, Eric
|
DCEG (NCI)
|
|
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer Agents
|
ZIC BC 010548
|
$244,114
|
$48,823
|
Figg, William
|
CCR (NCI)
|
|
Hodgkin's families
|
ZIA CP004410 08167
|
$69,137
|
$65,680
|
Goldin, Lynn
|
DCEG (NCI)
|
|
Familial case-control study of lymphoproliferative malignancies and auto-immune d
|
ZIA CP005803 00355
|
$13,239
|
$2,648
|
Goldin, Lynn
|
DCEG (NCI)
|
|
ETIB Clinical Research Core
|
ZID BC 010963
|
$1,978,942
|
$197,894
|
Gress, Ronald
|
CCR (NCI)
|
|
Medical Oncology HIV-AIDS Clinical Research
|
ZID BC 011683
|
$226,739
|
$22,674
|
Gulley, James
|
CCR (NCI)
|
|
Hematopathology Diagnosis
|
ZIA BC 011070
|
$641,445
|
$192,433
|
Jaffe, Elaine
|
CCR (NCI)
|
|
Lymphoma Disease Discovery and Definition
|
ZIA SC 000550
|
$561,264
|
$56,126
|
Jaffe, Elaine
|
CCR (NCI)
|
|
Hematopathology Fellowship
|
ZIE BC 011241
|
$400,903
|
$100,226
|
Jaffe, Elaine
|
CCR (NCI)
|
|
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
|
ZIA BC 011334
|
$379,286
|
$18,964
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Development of fully-human anti-CD30 chimeric antigen receptors
|
ZIA BC 011660
|
$95,505
|
$76,404
|
Kochenderfer, James
|
CCR (NCI)
|
|
Mechanisms of transcription factor integration at the c-myc promoter
|
ZIA SC 009144
|
$351,735
|
$35,173
|
Levens, David
|
CCR (NCI)
|
|
Cancer and Other Mortality Risks in a Cohort of U.S. Radiologic Technologists
|
ZIA CP010133 04180
|
$145,295
|
$2,906
|
Linet, Martha
|
DCEG (NCI)
|
|
Cancer following radiotherapy for benign gynecologic disorders
|
ZIA CP010131 04021
|
$30,751
|
$1,845
|
Little, Mark
|
DCEG (NCI)
|
|
Hemopoietic malignancies among persons exposed to low and moderate ionizing radia
|
ZIA CP010131 10715
|
$61,503
|
$6,150
|
Little, Mark
|
DCEG (NCI)
|
|
CCSS circulatory disease
|
ZIA CP010132 10623
|
$97,109
|
$19,422
|
Little, Mark
|
DCEG (NCI)
|
|
Low dose and low dose-rate cancer risk
|
ZIA CP010132 10681
|
$11,818
|
$1,773
|
Little, Mark
|
DCEG (NCI)
|
|
The Incidence of Breast and other Cancers among Female Flight Attendants
|
ZIA CP010133 04077
|
$16,720
|
$334
|
Little, Mark
|
DCEG (NCI)
|
|
Study of Structures of CCR5 and Its Interactions with CCR5 Inhibitors
|
ZIA BC 011109
|
$40,724
|
$2,036
|
Mitsuya, Hiroaki
|
CCR (NCI)
|
|
Childhood cancer survivor study (CCSS)
|
ZIA CP010131 04033
|
$11,662
|
$1,749
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Radiation dose- response and second primary cancers of stomach, esophagus, and
|
ZIA CP010131 04134
|
$1,076
|
$161
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Genomics of multiple primary tumors
|
ZIA CP010131 10782
|
$30,751
|
$3,075
|
Morton, Lindsay
|
DCEG (NCI)
|
|
DNA repair
|
ZIA BC 010283
|
$1,309,141
|
$222,554
|
Nussenzweig, Andre
|
CCR (NCI)
|
|
Molecular Mechanisms of Cancer Development
|
ZIC BC 011842
|
$162,782
|
$8,139
|
Pack, Svetlana
|
CCR (NCI)
|
|
Development of FISH Molecular Diagnostics to support Clinical Trials at NCI
|
ZID BC 011792
|
$244,173
|
$12,209
|
Pack, Svetlana
|
CCR (NCI)
|
|
Post-Transcriptional Regulation of Interleukin-7 Receptor Expression
|
ZIA BC 011214
|
$613,782
|
$122,756
|
Park, Jung-Hyun
|
CCR (NCI)
|
Total relevant funding to Hodgkins disease for this search: $13,282,652
|